ZURICH/LONDON (Reuters) - Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group's ability to personalize cancer care.
Original Article: Roche pays $2.4 billion for rest of cancer expert Foundation Medicine